Conference Presentation, Fireside Chat, Interview
Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
- Alnylam aims to address 100% of the genome using RNAi technology, projecting a generational opportunity compared to the approximately 25% coverage of small molecules or biologics, and expects AI, including Alpha Fold and large language models, to reduce drug discovery costs and accelerate development in the fairly near term.
- The company plans to expand its pipeline to 25 clinical programs by 2025, with a current six-year track record of delivering six new liver-targeted medicines, while maintaining a 55% clinical success rate that far exceeds the 8% rate for other modalities.
- Strategic focus includes advancing treatments for hypertension (affecting 60 million people globally) and CNS diseases like Alzheimer's and Huntington's, with a specific goal to deliver RNAi to every major tissue in the body by 2030, which could fundamentally alter medical textbooks.
- Financial and operational objectives include achieving sustainable non-GAAP profitability by the end of the current year and ranking among the top five biotech companies within the next five years, driven by the foreseeable revenue growth of its TTR amyloidosis flagship franchise.
- Management anticipates a decade or more typically elapsing between genetic knowledge publication and therapeutic translation, noting a 15 to 20-year historical lag for similar innovations, and expects large language models to significantly impact study design, patient enrollment, and regulatory submissions.
- Potential risks involve maintaining mission and culture while scaling, specifically preserving a patient-focused approach, and navigating anticipated stormy conditions in the biotech industry that will require resilience and adaptability.
- The outlook includes a recognition of persistent barriers for women in biopharmaceutical leadership, with the expectation that increased female seniority will shift traditional assumptions regarding leadership roles.